Fractional mass filtering as a means to assess circulating metabolites in early human clinical studies.
Recent changes in the regulatory environment have led to a need for new methods to assess circulating human drug metabolites in early clinical studies with respect to their potential toxicological impact. The specific goals of such studies are to determine if the metabolites present in human plasma following administration of a drug candidate also are observed in plasma from the animal studies employed for preclinical toxicological evaluation, and to estimate corresponding exposure margins (animal:human) for the major metabolites. Until recently, the accepted best practice for the characterization of circulating drug metabolites utilized liquid chromatography/tandem mass spectrometry (LC/MS/MS)-based methodologies, in conjunction with authentic chemical standards, for the detection and quantitative analyses of metabolites predicted from both animal studies and experiments with human liver preparations in vitro. While this approach is satisfactory for anticipated biotransformation products, metabolites that were not expected to circulate in human plasma frequently escape detection. Current accurate mass instruments enable the use of the technique of fractional mass filtering to detect both expected and unexpected metabolites in a rapid, less resource-intensive and more robust manner. Application of this technology to several clinical development programs at Merck Research Laboratories has demonstrated the value of fractional mass filtering in the assessment of circulating drug metabolites in early clinical trials.
Tiller
Philip R
PR
Merck Research Laboratories, West Point, PA 19486, USA. philip_tiller@merck.com
Yu
Sean
S
Bateman
Kevin P
KP
Castro-Perez
Jose
J
McIntosh
Ian S
IS
Kuo
Yushin
Y
Baillie
Thomas A
TA
D000818:Animals; D019380:Anti-HIV Agents / Q000032:analysis / Q000097:blood / Q000378:metabolism*; D002853:Chromatography, Liquid / Q000379:methods; D004285:Dogs; D004353:Drug Evaluation, Preclinical; D006801:Humans; D013058:Mass Spectrometry / Q000379:methods; D008862:Microsomes, Liver / Q000378:metabolism; D004364:Pharmaceutical Preparations / Q000032:analysis / Q000097:blood / Q000378:metabolism; D051381:Rats; D012984:Software; D053719:Tandem Mass Spectrometry / Q000379:methods*
D019380:Anti-HIV Agents; D004364:Pharmaceutical Preparations